TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum Tolerated Dose (MTD) of Carfilzomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients That Achieve a Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood GL-3 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sexually transmitted disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Perinatal outcomes (e.g., birth weight, gestational age)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: pathological complete response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual clarity during shoulder arthroscopic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduce AF incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: preserve natural AV conduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: effects on LV function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean energy density of food items purchased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Size of the uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of time in target range for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increment of teeth with cavitated lesions, restorations or extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Presence of potentially pathogenic seawater germs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increasing soft tissue facial measurement-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increasing soft tissue facial measurement-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increasing soft tissue facial measurement-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frequency of Days With Heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with detrusor contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urinary outcomes
Primary endpoint: Change from Baseline in Functional Assessment of Cancer Therapy-Ovarian (FACT-O)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in Functional Assessment of Cancer Therapy-Fatigue (FACT-F)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from Baseline in Short Form 36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Child change in body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent of dyssynergic defecation diagnosed by manometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: P2Y12 reaction units (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of manifestations of arthropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Volume of removed carious tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from study-related Major Adverse Cardiac and Neurological Events (MACNE)
Endpoint domain: Adverse events/effects
Primary endpoint: level of mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swimming time trials performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Metabolic Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Elevation of levels of Emotional Intelligence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of anesthesia recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knee and popliteus inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Biomechanical running technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Microalbumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year disease free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of combination treatment on pancreatic cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in metabolism in cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in circulating tumor DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Determination of malignant esophageal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Effect of the procedure on weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of detection of thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma vitamin K levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-versus-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative reduction of bacterial counts from blood cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients with any reduction of bacterial counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Visibility of entire catheter length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of catheter tip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood testosterone concentration maintained below 50ng/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants Who Withdrew Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving PASI 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving sPGA of Clear or Almost Clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of subclinical fluid overload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drusen area and volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Laboratory Changes (ALC)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Cerebral Desaturation Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: metabolic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median Number of NMOSD Attacks Per Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax Concentration Maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax time of maximum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Area under curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C12h concentration in plasma 12 hours after infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway geometry and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in P2X7R-inflammasome activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in NFkB activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in serum α-synuclein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in serum IL-1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in serum IL-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Weekly episodes of fecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sweat Chloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Month Change in FEV1 Percent Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Self Report on Visual Analog Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without need for further diagnostic imaging
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: rate of complete ST-segment resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite of all-cause death or recurrent target vessel myocardial infarction (TV re-MI)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of serogroup A meningococci disease
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Philadelphia Naming Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of the Sensorial Supraclavicular Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serenat scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time to local progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of time with sensed glucose less than 70 mg/dl post-exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Isolation of Clostridium difficile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in global photographic assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ambulance dispatch
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ambulance transport
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ED visit, 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: ED visit, 6 months
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Primary care visit, 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Primary care visit, 6 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 911 use, 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in Cryptosporidium fecal shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Progression Free Survival (PFS) at Week 24
Endpoint domain: Mortality/survival
Primary endpoint: Presence or absence of hypointense phase rim around lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects satisfying NCEP-ATP III criteria for metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fugl Meyer Assessment - Upper Limb (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients with 50% or more increase in SCr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Days to resolution of cough, fever and shortness of breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater Reliability of the Clinician Erythema Assessment (CEA) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intra-rater Reliability of the CEA Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of the B-line score from inclusion to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of pleural line irregularity from inclusion to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of pleural line thickness from inclusion to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Helicobacter pylori reinfection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ablation efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Solicited Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of graft failure
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of grades III-IV acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Magnitude of platelet aggregation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With (All Causality) Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: change in probing pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in bleeding on probing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H max to M max amplitude ratio (H/ M ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum H reflex amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clostridiales abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who have not experienced any severe vaso-occlusive crisis (VOC) for at least 12 consecutive months (VF12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of transplant-related mortality (TRM) within 1 year after CTX001 infusion
Endpoint domain: Mortality/survival
Primary endpoint: Ankle Osteoarthritis Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT data to measure cartilage distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improved joint function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decision to change management
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Edinburgh Postnatal Depression Score (EPDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Reported Pain and Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of PDT treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participant Completing the Questionnaire Within 15 Minutes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cost Per Completed Survey
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fibromyalgia Impact Questionnaire Revised (FIQR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sleep Quality (Pittsburgh Sleep Quality Index)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Total urine sugar per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood endotoxin and cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of greater than or equal to 50% stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Social-psychological
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Sustained Virologic Response 24 Weeks Following Completion of Treatment (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss (absolute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular (CV) health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concordance coefficient between tears and cerebrospinal fluid analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Resistance Pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bacterial isolate genomic characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Who Experienced at Least 1 Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Treatment Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Length of antibiotic treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: The number of intraoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: The inducibility of the clinical VT at the end of ablation procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The number of recurrent ventricular tachycardias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The number of episodes of ICD therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrent hiatal hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change scores for depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change scores for Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in PDQ-39 total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sustained Virologic Response (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of trocar site hernia development
Endpoint domain: Adverse events/effects
Primary endpoint: Net change in systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Serious Bacterial Infections (SBIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Histological status of AK target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriologic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Disease activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability assessed by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Preliminary anti-tumor activity assessed by radiological scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Memory problems perceptions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Best Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and number of hospitalization for cardiovascular cause
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage incidence of mortality
Endpoint domain: Mortality/survival
Primary endpoint: percentage incidence of morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase II dose of GMX1777
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Disease response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects of GMX1777 in combination with temozolomide
Endpoint domain: Adverse events/effects
Primary endpoint: Change in species diversity after omeprazole treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergence of signature taxa after omeprazole treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep-related Functional Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning